Abstract
Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence ( 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.
| Original language | German |
|---|---|
| Pages (from-to) | 19-23 |
| Number of pages | 5 |
| Journal | Aktuelle Urologie |
| Volume | 29 |
| Issue number | 1 |
| State | Published - Feb 1998 |
Fingerprint
Keywords
- Prostate specific antigen
- Review
- Velocity
ASJC Scopus subject areas
- Nephrology
Cite this
PSA-velocity bei prostataerkrankungen. / Thiel, R.; Pearson, J. D.; Carter, H Ballentine.
In: Aktuelle Urologie, Vol. 29, No. 1, 02.1998, p. 19-23.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PSA-velocity bei prostataerkrankungen
AU - Thiel, R.
AU - Pearson, J. D.
AU - Carter, H Ballentine
PY - 1998/2
Y1 - 1998/2
N2 - Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence ( 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.
AB - Prostate-specific velocity (rate of change) is a method for assessing the risk of prostate cancer in an individual and for distinguishing prostatic adenoma from prostatic cancer. Using a PSA velocity (PSAV) cut-off point of 0.75 ng/ml per year, sensitivity among men with prostate cancer was 70% and specificity among men without prostate cancer was 95%. Therefore, the validity of PSAV is higher than the interpretation of a single PSA value. PSAV allows detection of prostate cancer an average of 5 years earlier than its clinical manifestation. In patients after radical prostatectomy, PSAV can help to distinguish local recurrence ( 0.75 ng/ml/year). Currently, the validity of PSAV is low in staging and assessing the prognosis of prostate cancer. Routine use of this concept requires the analysis of several PSA values (preferably of the same assay) over a time span of 1.5 to 2 years.
KW - Prostate specific antigen
KW - Review
KW - Velocity
UR - http://www.scopus.com/inward/record.url?scp=0032361313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032361313&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0032361313
VL - 29
SP - 19
EP - 23
JO - Aktuelle Urologie
JF - Aktuelle Urologie
SN - 0001-7868
IS - 1
ER -